{"id":"mdr-101","safety":{"commonSideEffects":[{"rate":null,"effect":"Transaminitis (elevated liver enzymes)"},{"rate":null,"effect":"Immune response to AAV vector"},{"rate":null,"effect":"Respiratory adverse events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABCA3 mutations cause defective surfactant metabolism, leading to progressive lung disease. MDR-101 uses an adeno-associated viral (AAV) vector to deliver a working ABCA3 gene directly to lung cells, enabling them to produce functional ABCA3 protein and restore normal surfactant homeostasis. This addresses the underlying genetic defect rather than treating symptoms.","oneSentence":"MDR-101 is a gene therapy that delivers a functional copy of the ABCA3 gene to restore surfactant production in patients with ABCA3-deficient interstitial lung disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:26.127Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"ABCA3-deficient interstitial lung disease"}]},"trialDetails":[{"nctId":"NCT03363945","phase":"PHASE3","title":"Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants","status":"COMPLETED","sponsor":"Medeor Therapeutics, Inc.","startDate":"2018-03-15","conditions":"Kidney Transplant Rejection","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MDR-101","genericName":"MDR-101","companyName":"Medeor Therapeutics, Inc.","companyId":"medeor-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"MDR-101 is a gene therapy that delivers a functional copy of the ABCA3 gene to restore surfactant production in patients with ABCA3-deficient interstitial lung disease. Used for ABCA3-deficient interstitial lung disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}